Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription

Journal of Inflammation

Volumn 5, Issue , 2008, Pages

  Hale, Laura P ^a   Cianciolo, George ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[2 AMINO 6 CHLORO 9 5(DIHYDROXYBORYLPENTYL) PURINE]; DEXTRAN SULFATE; INTERLEUKIN 10; LMP 420; PIROXICAM; PURINE NUCLEOSIDE DERIVATIVE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; COLITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG STRUCTURE; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEMALE; HISTOLOGY; LONGITUDINAL STUDY; MOUSE; NONHUMAN; T LYMPHOCYTE; WILD TYPE;

MUS;

EID: 42249101239     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-5-4     Document Type: Article

References (32)

1. Immunity, inflammation, and allergy in the gut. TT MacDonald G Monteleone, Science 2005 307 1920 1925 10.1126/science.1106442 15790845
2. Inflammatory bowel disease. DK Podolsky, New Engl J Med 2002 347 417 429 10.1056/NEJMra020831 12167685
3. Cytokines, chemokines, and growth factors in the pathogenesis and treatment of inflammatory bowel disease. D O'Neil L Steidler, Adv Exp Med Biol 2003 520 252 285 12613583
4. Chemokines in inflammatory bowel disease. KA Papadakis, Curr Allergy Asthma Reports 2004 4 1 83 89 10.1007/s11882-004-0048-7 14680627
5. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. DM Knight H Trinh J Le S Siegel D Shealy M McDonough B Scallon MA Moore J Vilcek P Daddona J Ghrayeb, Molec Immunol 1993 30 1443 1453 10.1016/0161-5890(93)90106-L
6. Binding and functional comparison of two types of tumor necrosis factor antagonists. B Scallon A Cai N Solowski A Rosenberg XY Song D Shealy C Wagner, J Pharmacol Exp Ther 2002 301 418 426 10.1124/jpet.301.2.418 11961039
7. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. JM Van den Brande H Braat GR van den Brink HH Versteeg CA Bauer I Hoedemaeker C van Montfrans DW Hommes MP Peppelenbosch SJ van Deventer, Gastroenterol 2003 124 1774 1785 10.1016/S0016-5085(03)00382-2
8. PDR (Physicians Desk Reference), Thomson PDR, Montvale, NJ, 61 2007 584 591 971-979
9. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. PH Wooley J Dutcher MB Widmer S Gillis, J Immunol 1993 151 6602 6607 8245488
10. Treatment of rheumatoid arthritis by TNF-blocking agents. W Graninger J Smolen, Int Arch Allergy Immunol 2002 127 10 14 10.1159/000048164 11893849
11. Etanercept as monotherapy in patients with psoriasis. CL Leonardi JL Powers RT Matheson BS Goffe R Zitnik A Wang AB Gottlieb, New Engl J Med 2003 349 2014 2022 10.1056/NEJMoa030409 14627786
12. Infliximab for the treatment of fistulas in patients with Crohn's disease. DH Present P Rutgeerts S Targan SB Hanauer L Mayer RA van Hogezand DK Podolsky BE Sands T Braakman KL DeWoody TF Schaible SJ van Deventer, N Engl J Med 1999 340 1398 1405 10.1056/NEJM199905063401804 10228190
13. Infliximab treatment of rheumatoid arthritis and Crohn's disease. IK Nahar K Shojania CA Marra AH Alamgir AH Anis, Ann Pharmacol 2003 37 9 1256 1265 10.1345/aph.1C039 12921510
14. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. SB Hanauer BG Feagan GR Lichtenstein LF Mayer s Schreiber JF Colombel D Rachmilewicz DC Wolf A Olson W Bao P Rutgeerts, Lancet 2002 359 1541 1549 10.1016/S0140-6736(02)08512-4 12047962
15. Infliximab maintenance therapy for fistulizing Crohn's disease. BE Sands FH Anderson CN Bernstein WY Chey BG Feagan RN Fedorak MA Kamm JR Korzenik BA Lashner JE Onken D Rachmilewitz P Rutgeerts G Wild DC Wold PA Marsters Travers Suzanne MA Blank SJ van Deventer, New Engl J Med 2004 350 876 885 10.1056/NEJMoa030815 14985485
16. Infliximab for induction and maintenance therapy for ulcerative colitis. P Rutgeerts WJ Sandborn BG Feagan W Reinisch A Olson J Johanns S Travers D Rachmilewitz SB Hanauer GR Lichtenstein WJS de Villiers D Present BE Sands JF Colombel, New Engl J Med 2005 353 2462 2476 10.1056/NEJMoa050516 16339095
17. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. WJ Sandborn SB Hanauer S Katz M Safdi DG Wolf RD Baerg WJ Tremaine T Johnson NN Diehl AR Zinmeister, Gastroenterol 2001 121 5 1088 1094 10.1053/gast.2001.28674 11677200
18. Etanercept for Crohn's disease. TS Kupper, New Engl J Med 2004 350 840 10.1056/NEJM200402193500818
19. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. GS Gottlieb CF Lesser KK Holmes A Wald, Clin Infect Dis 2003 37 838 840 10.1086/377235 12955647
20. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. CA Hage KL Wood HT Winer-Muram SJ Wilson G Sarosi KS Knox, Chest 2003 124 2395 2397 10.1378/chest.124.6.2395 14665529
21. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. J Keane S Gershon RP Wise E Mirabile-Levens J Kasznica WD Schwieterman JN Siegel MM Braun, New Engl J Med 2001 345 1098 1104 10.1056/NEJMoa011110 11596589
22. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. MA Gardam EC Keystone R Menzies S Manners E Skamene R Long DC Vinh, Lancet Inf Dis 2003 3 3 148 155 10.1016/S1473-3099(03) 00545-0 12614731
23. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. F Wolfe K Michaud J Anderson K Urbansky, Arthritis Rheum 2004 50 372 379 10.1002/art.20009 14872478
24. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines. BJ Benson X Chen GJ Cianciolo J-L Diaz KS Ishaq SL Morris-Natschke RJ Uhing H Wong, US Patent 5,643,893 1997
25. LMP-420, a small-molecule inhibitor of TNF-alpha transcription, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. S Haraguchi NK Day W Kamchaisatian M Beigier-Pompadre S Stenger N Tangsinmankong JW Sleasman SV Pizzo GJ Cianciolo, AIDS Res & Ther 2006 3 8 16573838 10.1186/1742-6405-3-8
26. Piroxicam treatment of IL-10 deficient mice enhances colon epithelial apoptosis and mucosal exposure to intestinal bacteria. LP Hale MR Gottfried A Swidsinski, Inflamm Bowel Dis 2005 11 1060 1069 10.1097/01.MIB.0000187582.90423. bc 16306768
27. Helicobacter-induced inflammatory bowel disease in IL-10 and T cell-deficient mice. A Burich R Hershberg K Waggie W Zeng T Brabb G Westrich JL Viney L Maggio-Price, Am J Physiol Gastrointest Liver Physiol 2001 281 G764 G778 11518689
28. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. LA Dieleman BU Ridwan GS Tennyson KW Beagley RP Bucy CO Elson, Gasroenterol 1994 107 6 1643 1652 7958674
29. A virus-like particle-based vaccine selectively targeting soluble TNF-α protects from arthritis without inducing reactivation of latent tuberculosis. G Spohn R Guler P Johansen I Keller M Jacobs M Bek F Rohner M Bauer K Dietmeier TM Kundig GT Jennings F Brombacher MF Bachmann, J Immunol 2007 178 7450 7457 17513796
30. Antiserum to tumor necrosis factor and failure to prevent murine colitis. AD Olson EA DelBuono KN Bitar DG Remick, J Pediatr Gastroenterol Nutr 1995 21 410 8583292
31. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. Y Naito T Takagi O Handa T Ishikawa S Nakagawa T Yamaguchi N Yoshida M Minami M Kita J Imanishi T Yoshikawa, J Gastroenterol Hepatol 2003 18 560 569 10.1046/j.1440-1746.2003.03034.x 12702049
32. Robbins and Cotran Pathologic Basis of Disease. V Kumar AK Abbas N Fausti, Elsevier Saunders. Philadelphia, PA 7 2005 10 11